References
  1. McConathy J, Owens MJ. Stereochemistry in Drug Action. Prim Care Companion J Clin Psychiatry. 2003;5(2):70-73. https://doi.org/10.4088/pcc.v05n0202.
  2. Abram M, Jakubiec M, Kaminski K. Chirality as an important factor for the development of new antiepileptic drugs. Chem Med Chem. 2019;20(14):1744-1761. https://doi.org/ 10.1002/cmdc.201900367.
  3. Smith SW. Chiral toxicology: it’s the same thing…only different. Toxicol Sci. 2009;110(1):4-30. https://doi.org/10.1093/toxsci/kfp097.
  4. Wei X, Liu J, Xia GJ, Deng J, Sun P, Chruma JJ, Wu W, Yang C, Wang YG, Huang Z. Enantioselective photoinduced cyclodimerization of a prochiral anthracene derivative adsorbed on helical metal nanostructures. Nat Chem. 2020;12(6):551-559. https://doi.org/10.1038/s41557-020-0453-0.
  5. Chmielewska A, Konieczna L, Bączek T. A novel two-step liquid-liquid extraction procedure combined with stationary phase immobilized human serum albumin for the chiral separation of cetirizine enantiomers along with M and P parabens. Molecules. 2016;21(12):1654. https://doi.org/10.3390/molecules21121654.
  6. Tillement JP, Testa B, Brée F. Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem Pharmacol. 2003;66(7):1123-6. https://doi.org/10.1016/s0006-2952(03)00558-6.
  7. Blaschke G, Kraft HP, Fickentscher K, Köhler F. Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers. Arzneim.-Forsch. 1979;29(10):1640-1642.
  8. Tokunaga E, Yamamoto T, Ito E, Shibata N. Understanding the thalidomide chirality in biological processes by the self-disproportionation of enantiomers. Sci Rep. 2018;8(1):17131. https://doi.org/10.1038/s41598-018-35457-6.
  9. Agranat I, Caner H. Intellectual property and chirality of drugs. Drug Discovery Today. 1999;4(7):313-321. https://doi.org/10.1016/s1359-6446(99)01363-x.
  10. Gal J. New single-isomer compounds on the horizon. CNS Spectr. 2002;7(4 Suppl 1):45-54. https://doi.org/10.1017/S1092852900028601.
  11. Tucker GT. Chiral switches. Lancet. 2000;355(9209):1085-7. https://doi.org/10.1016/S0140-6736(00)02047-X.
  12. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10. https://doi.org/10.1186/s12916-016-0553-2.
  13. NIH National Center for Advancing Translational Sciences. Inxight: Drugs. https://drugs.ncats.ioAccessed 13 Jan 2022.
  14. Nguyen LA, He H, Pham-Huy C. Chiral drugs: an overview. Int J Biomed Sci. 2006;2(2):85-100.
  15. Katzung BG. Introduction: The Nature of Drugs & Drug Development & Regulation. In: Katzung BG, eds. Basic & Clinical Pharmacology. 15th ed. McGraw-Hill Education: US; 2020.p: 1-20.
  16. Caner H, Groner E, Levy L, Agranat I. Trends in the development of chiral drugs. Drug Discov Today. 2004;9(3):105-10. https://doi.org/10.1016/s1359-6446(03)02904-0.
  17. Lennard MS. Clinical pharmacology through the looking glass: reflections on the racemate vs enantiomer debate. Br J Clin Pharmacol. 1991;31(6):623-625. https://doi.org/10.1111/j.1365-2125.1991.tb05583.x.
  18. Mwamwitwa KW, Kaibere RM, Fimbo AM, Sabitii W, Ntinginya NE, Mmbaga BT, Shewiyo DH, Shearer MC, Smith AD, Kaale EA. A Retrospective Cross-sectional Study to Determine Chirality Status of Registered Medicines in Tanzania. Sci Rep. 2020;10(17834). https://doi.org/10.1038/s41598-020-74932-x.
  19. Lin GQ, Zhang JG, Cheng JF. Overview of Chirality and Chiral Drugs. In: Chiral Drugs: Chemistry and Biological Action, 1st ed. Eds: Lin GQ, Zhang JG, Cheng JF. John Wiley & Sons, Inc. 2011, p. 3–28. https://doi.org/10.1002/9781118075647.ch1.
  20. Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov. 2002;1(10):753-768. https://doi.org/10.1038/nrd915.
  21. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs, 2021. Oslo, Norway 2020. https://www.whocc.no/atc_ddd_index/ Accessed 29 Dec 2021.
  22. Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E. Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999. Drug Inf J. 2001;35(1):293-317. https://doi.org/10.1177/009286150103500134.
  23. Inotai A, Hankó B, Mészáros Á. Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. Pharmacoepidemiol Drug Saf. 2010;19(2):183–90. https://doi.org/10.1002/pds.1893.
  24. Ranade VV, Somberg JC. Chiral cardiovascular drugs: an overview. Am J Ther. 2005;12(5):439-59. https://doi.org/10.1097/01.mjt.0000167429.37357.0c.
  25. Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83-94. https://doi.org/10.1016/j.jsps.2013.02.003.
  26. Gross AS, Somogyi A, Eichelbaum M. Stereoselective Drug Metabolism and Drug Interactions. In: Eichelbaum M, Somogyi A eds, Stereochemical Aspects of Drug Action and Disposition. Handbook of Experimental Pharmacology, vol 153. Berlin: Springer; 2003, p:313-339. https://doi.org/10.1007/978-3-642-55842-9_13.
  27. Faber K, Griengl H. Chirality in Organic Synthesis — The Use of Biocatalysts. In: Janoschek R., eds. Chirality. Berlin: Springer; 1991, p:103-140.
  28. European Association for the Study of the Liver. EASL clinical practice guidelines: Drug-induced liver injury. J Hepatol 2019;70:1222-61. https://doi.org/10.1016/j.jhep.2019.02.014.
  29. Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol. 2005;35(4):325-61. https://doi.org/10.1080/10408440590935620.
  30. Jamal S, Ali W, Nagpal P, Grover S, Grover A. Computational models for the prediction of adverse cardiovascular drug reactions. J Transl Med. 2019;17(1):171. https://doi.org/10.1186/s12967-019-1918-z.
  31. Blaser HU. Chirality and its implications for the pharmaceutical industry. Rend. Fis. Acc. Lincei 2013;24:213–216. https://doi.org/10.1007/s12210-012-0220-2.